These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A simple assay method for factor X (Stuart-Prower factor). HOUGIE C Proc Soc Exp Biol Med; 1962 Mar; 109():754-6. PubMed ID: 14449283 [No Abstract] [Full Text] [Related]
3. [STUDY OF THE MECHANISM OF ACTION OF STUART-PROWER FACTOR (FACTOR X) IN THE FORMATION OF ENDOGENOUS THROMBOPLASTIN]. ASCARI E; BARBIERI U; GOBBI F Minerva Med; 1964 Oct; 55():3210-5. PubMed ID: 14231296 [No Abstract] [Full Text] [Related]
4. Congenital coagulation deficiency of Stuart factor activity. GONYEA LM; KRIVIT W J Lab Clin Med; 1958 Mar; 51(3):398-409. PubMed ID: 13514252 [No Abstract] [Full Text] [Related]
5. Factors influencing the consumption of factor X (Stuart-Prower factor) during intrinsic coagulation. Niemetz J Thromb Diath Haemorrh; 1967 Dec; 18(3-4):332-41. PubMed ID: 4952976 [No Abstract] [Full Text] [Related]
7. [Hemorrhagic diathesis and activity of the antihemophilic factor in women]. VERSTRAETE M; VANDENBROUCKE J Rev Hematol; 1955; 10(4):665-73. PubMed ID: 13311037 [No Abstract] [Full Text] [Related]
8. [Sharing by the activated forms of precursors and plasmatic components of thromboplastin (PTA, PTC) and by the Stuart-Prower factor in the formation of the coagulo-accelerating principle of the serum]. Nenci GG; Lechler E Haematologica; 1967; 52(4):309-20. PubMed ID: 4976387 [No Abstract] [Full Text] [Related]
9. Factor-V consumption during blood coagulation. DOUGLAS AS Br J Haematol; 1956 Apr; 2(2):153-9. PubMed ID: 13315900 [No Abstract] [Full Text] [Related]
10. Review of the present status of other clotting factors: e) Factor X (Stuart-Prower factor). GRAHAM JB; HOUGIE C Thromb Diath Haemorrh; 1961; 6(Suppl 1)():416-20. PubMed ID: 13949772 [No Abstract] [Full Text] [Related]
11. Blood coagulation as a continuous process. II. The turnover rate of proconvertin. ROOS J; van ARKEL ; KEUTER EJ; BALLIEUX RE Acta Med Scand; 1960 Dec; 168():477-82. PubMed ID: 13743183 [No Abstract] [Full Text] [Related]
12. [Research on the mechanism of action of proaccelerin (factor V, labile factor). IV. The evolution of proacellerin during blood coagulation in normal and pathological conditions]. GOBBI F; BARBIERI U; ASCARI E Prog Med (Napoli); 1961 Dec; 17():814-22. PubMed ID: 13899356 [No Abstract] [Full Text] [Related]
13. [Blood coagulation disorder in a 7-year-old child with a partial factor X or Stuart-Prower factor deficiency]. Violante N; Ciavarella N Haematologica; 1972; 58(9):587-93. PubMed ID: 4206233 [No Abstract] [Full Text] [Related]
15. The specific assay of Prower-Stuart factor and factor VII. DENSON KW Acta Haematol; 1961 Feb; 25():105-20. PubMed ID: 13721923 [No Abstract] [Full Text] [Related]
16. [BLOOD COAGULATION IN FACTOR XI DEFICIENCY]. CZERWINSKA KOSSOBUDZKA B; KOTSCHY M; SMOLIK R Pol Arch Med Wewn; 1963; 33():597-614. PubMed ID: 14064359 [No Abstract] [Full Text] [Related]
17. Stuart-Prower factor in newborn infants. SCHULZ J; VAN CREVELD S Etudes Neonatales; 1958 Dec; 7(4):133-42. PubMed ID: 13619632 [No Abstract] [Full Text] [Related]
18. The Stuart-Prower factor: utilization of clotting factors obtained by starch-block electrophoresis for genetic evaluation. RABINER SF; KRETCHMER N Br J Haematol; 1961 Jan; 7():99-111. PubMed ID: 13738819 [No Abstract] [Full Text] [Related]
19. [THEORIES CONCERNING FACTOR X (STUART-PROWER) IN LIVER DISEASES AND IN TREATMENT WITH INDIRECT ANTICOAGULANTS]. PARREIRA F; ANTUNES ML; SEQUEIRA J; NUNES V J Soc Cienc Med Lisb; 1964 Mar; 128():179-92. PubMed ID: 14151145 [No Abstract] [Full Text] [Related]
20. [FUNCTIONAL STATE OF THE BLOOD COAGULATION SYSTEM IN HEMORRHAGIC VASCULITIS]. VAISMAN SR; KOPTEVA Ia Ter Arkh; 1965 Mar; 37():93-7. PubMed ID: 14274620 [No Abstract] [Full Text] [Related] [Next] [New Search]